IQVIA Holdings Inc. (NYSE:IQV) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• IQVIA has a “Moderate Buy” consensus rating from 17 analysts, including 12 buys and two strong buys. The average 12-month price target is $274.31, with several firms recently raising their targets as high as $300.
• IQVIA reported quarterly EPS of $3.15, beating the $3.03 consensus estimate, while revenue reached $4.37 billion and increased 8.7% year over year. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• Shares opened at $262.32, near their 52-week high of $277.40, while insiders have sold 15,581 shares worth approximately $3.8 million over the past 90 days. Institutional investors own 89.62% of the company.

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has received an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $274.31.

Several research firms have recently commented on IQV. Stifel Nicolaus lifted their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Robert W. Baird upped their target price on IQVIA from $252.00 to $287.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. Mizuho raised their price target on IQVIA from $275.00 to $300.00 and gave the stock an "outperform" rating in a report on Wednesday, October 7th. Morgan Stanley upped their price objective on IQVIA from $240.00 to $270.00 and gave the stock an "equal weight" rating in a research note on Thursday, September 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research report on Thursday, July 9th.

Insider Buying and Selling

In related news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 15,581 shares of company stock valued at $3,796,021. Company insiders own 1.70% of the company's stock.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently bought and sold shares of the business. Compass Financial Management LLC acquired a new position in shares of IQVIA during the 2nd quarter valued at about $27,000. Financial Freedom LLC bought a new position in shares of IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the 1st quarter worth approximately $25,000. Elevation Wealth Partners LLC lifted its holdings in IQVIA by 218.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company's stock worth $30,000 after purchasing an additional 105 shares during the last quarter. Finally, Caitlin John LLC bought a new stake in IQVIA during the second quarter worth approximately $31,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 0.9%

Shares of NYSE IQV opened at $262.32 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock's 50 day moving average price is $258.23 and its two-hundred day moving average price is $210.39. IQVIA has a 52-week low of $154.50 and a 52-week high of $277.40. The stock has a market capitalization of $43.18 billion, a P/E ratio of 32.55, a PEG ratio of 2.26 and a beta of 1.17.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. During the same period in the previous year, the business earned $2.81 EPS. The business's quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts anticipate that IQVIA will post 11.56 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.